$LLY just broke new ground—first pharma company to get a GLP-1 weight-loss pill approved in China. That's a massive market unlock. While Novo and others fight for share in the West, Lilly quietly slipped through the regulatory door in the world's second-largest economy. China's obesity rates are climbing, and the appetite for weight-loss drugs is real. This isn't just a headline—it's a strategic positioning move that could shift earnings expectations in a big way.